Clincosm LogoSign in Get a demo

Refractory Diffuse Large B-Cell Lymphoma

Showing 1 - 25 of 56
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6

Not yet recruiting
  • Grade 3b Follicular Lymphoma
  • +5 more
  • Biospecimen Collection
  • +9 more
  • (no location specified)
Jun 6, 2023

Recurrent DLBCL, Refractory DLBCL Trial in Duarte (procedure, biological, radiation)

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Biospecimen Collection
  • +6 more
  • Duarte, California
    City of Hope Medical Center
Mar 24, 2023

Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma Trial in Worldwide (DPX-Survivac,

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • Fountain Valley, California
  • +44 more
Jan 20, 2023

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6

Withdrawn
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +9 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2023

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Jacksonville, Florida
  • +11 more
Jan 12, 2023

Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +11 more
  • Biopsy
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United

Active, not recruiting
  • ALK-Positive Large B-Cell Lymphoma
  • +34 more
  • Phoenix, Arizona
  • +32 more
Jan 3, 2023

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 30, 2022

Cardiovascular Events Among Adults Relapsed or Refractory

Recruiting
  • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
  • +9 more
  • Electronic Health Record Review
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +5 more
  • Duarte, California
  • +3 more
Nov 17, 2022

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Duarte, California
  • +2 more
Nov 10, 2022

Recurrent DLBCL, Refractory DLBCL Trial in Houston (Chemotherapy, Computed Tomography, Fludeoxyglucose F-18)

Completed
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Oct 27, 2022

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in United Kingdom, United States (AUTO3)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • AUTO3
  • Duarte, California
  • +10 more
Oct 19, 2022

Relapsed DLBCL, Refractory DLBCL Trial in Hackensack (ABT-199, Ibrutinib, Rituximab)

Active, not recruiting
  • Relapsed Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Hackensack, New Jersey
    John Theurer Cancer Center at Hackensack University Medical Cent
Oct 7, 2022

Recurrent DLBCL, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory DLBCL Trial in Houston (drug, procedure, other, biological)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Recurrent DLBCL, Recurrent High Grade B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma Trial in United States

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +5 more
  • Mogamulizumab
  • Pembrolizumab
  • Sacramento, California
  • +7 more
Sep 15, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent DLBCL, Recurrent High Grade B-Cell Lymphoma Trial in Houston (Anakinra,

Active, not recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +8 more
  • Anakinra
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 22, 2022

DLBCL, Not Otherwise Specified, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Seattle

Terminated
Has Results
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +5 more
  • Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 1, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Non-hodgkin Lymphoma,B Cell, Refractory DLBCL, Relapsed DLBCL Trial in United States (MT-3724, Gemcitabine, Oxaliplatin)

Terminated
Has Results
  • Non-hodgkin Lymphoma,B Cell
  • +2 more
  • Orange, California
  • +8 more
Jul 18, 2022

Refractory Diffuse Large B-cell Lymphoma, Refractory DLBCL, Not Otherwise Specified, Recurrent DLBCL Trial in Duarte, Saint

Recruiting
  • Refractory Diffuse Large B-cell Lymphoma
  • +4 more
  • Duarte, California
  • +2 more
Aug 9, 2022

Relapsed DLBCL, Refractory DLBCL Trial in Worldwide (Loncastuximab Tesirine, Rituximab, Gemcitabine)

Recruiting
  • Relapsed Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Loncastuximab Tesirine
  • +3 more
  • La Jolla, California
  • +59 more
Aug 4, 2022

Relapsed Diffuse Large B-cell Lymphoma, Refractory DLBCL Trial in Worldwide (Polatuzumab Vedotin, Mabthera, Ifosfamide)

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • +4 more
  • Graz, Austria
  • +62 more
Aug 2, 2022